Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 14/20 | 1.00 |
| ▸ | FLT3 | P36888 | 8/20 | 0.73 |
| ▸ | IRAK1 | P51617 | 4/20 | 0.73 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.73 |
| ▸ | CDK7 | P50613 | 2/20 | 0.73 |
| ▸ | CCNH | P51946 | 2/20 | 0.73 |
| ▸ | LCK | P06239 | 1/20 | 0.73 |
| ▸ | RET | P07949 | 1/20 | 0.73 |
| ▸ | BLK | P51451 | 1/20 | 0.73 |
| ▸ | NRAS | P01111 | 5/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24231355 | 0.94 | IRAK4 (0.89) | IRAK4FLT3IRAK1PDGFRBCDK7 | |
| SCHEMBL22145731 | 0.90 | IRAK4 (1.00) | IRAK4FLT3IRAK1PDGFRBCDK7 | |
| SCHEMBL25989136 | 0.88 | IRAK4 (0.82) | IRAK4FLT3IRAK1PDGFRBCDK7 | |
| SCHEMBL26000499 | 0.88 | IRAK4 (0.82) | IRAK4FLT3IRAK1PDGFRBCDK7 | |
| SCHEMBL25991308 | 0.88 | IRAK4 (0.82) | IRAK4FLT3IRAK1PDGFRBCDK7 | |
| SCHEMBL24231557 | 0.87 | IRAK4 (0.77) | IRAK4FLT3IRAK1PDGFRBCDK7 | |
| SCHEMBL24231508 | 0.87 | IRAK4 (0.77) | IRAK4FLT3IRAK1PDGFRBCDK7 | |
| SCHEMBL22840774 | 0.86 | IRAK4 (0.77) | IRAK4FLT3IRAK1PDGFRBCDK7 | |
| SCHEMBL24231711 | 0.85 | IRAK4 (0.77) | IRAK4FLT3IRAK1PDGFRBCDK7 | |
| SCHEMBL24231349 | 0.85 | IRAK4 (0.73) | IRAK4FLT3IRAK1PDGFRBCDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303563-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER | 2023-09-28 | — | — | US | disclosed |
| US-11542261-B2 | Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220213094-A1 | Substituted Imidazo[l,2-a]-pyridines as IRAK 1/4 and FLT3 Inhibitors | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-07-07 | — | — | US | disclosed |
| US-11254667-B2 | Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-02-22 | — | — | US | disclosed |
| WO-2022026935-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-02-03 | — | — | WO | disclosed |
| EP-3854796-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS FOR TREATING DISEASES USING THEM, AND METHODS FOR PREPARING THEM | Children's Hospital Medical Center (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3500571-B1 | IMIDAZO[1,2-A]PYRIDIN COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS FOR TREATING DISEASES USING THEM, AND METHODS FOR PREPARING THEM | CHILDRENS HOSPITAL MED CT (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20200270242-A1 | COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES, AND METHODS FOR PREPARING COMPOUNDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-08-27 | — | — | US | disclosed |
| US-20200199123-A1 | COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES, AND METHODS FOR PREPARING COMPOUNDS | CHILDRENS HOSPITAL MED CT (US) | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199123-A1 | COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES, AND METHODS FOR PREPARING COMPOUNDS | IRAK1, IRAK2, IRAK3 | IRAK4 4/4885FLT3 63/4885IRAK1 1/4885 |
| US-11254667-B2 | Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors | IRAK1, IRAK4, FLT3 | IRAK4 2/4885FLT3 3/4885IRAK1 1/4885 |
| US-20220213094-A1 | Substituted Imidazo[l,2-a]-pyridines as IRAK 1/4 and FLT3 Inhibitors | IRAK1, IRAK4, FLT3 | IRAK4 2/4885FLT3 3/4885IRAK1 1/4885 |
| US-20200270242-A1 | COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES, AND METHODS FOR PREPARING COMPOUNDS | VHL, ETV6, C5 | IRAK4 1906/4885FLT3 549/4885IRAK1 1164/4885 |
| US-20230303563-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK2, IRAK3 | IRAK4 5/4885FLT3 1/4885IRAK1 4/4885 |
| US-11542261-B2 | Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885FLT3 5/4885IRAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.